{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:51:51Z","timestamp":1785901911018,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Fonds National de la Recherche Scientifique"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.thromres.2017.06.034","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T18:45:12Z","timestamp":1498675512000},"page":"29-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3499-1466","authenticated-orcid":false,"given":"Anne-Laure","family":"Sennesael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Exner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Chatelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lessire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Larock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Vancraeynest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Pochet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Dogn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Spinewine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2017.06.034_bb0005","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jth.12149","article-title":"Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis","volume":"11","author":"Baglin","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0010","first-page":"326","article-title":"Why, when and how to monitor new oral anticoagulants","volume":"10","author":"Tamigniau","year":"2014","journal-title":"Rev. Med. Suisse"},{"key":"10.1016\/j.thromres.2017.06.034_bb0015","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jacc.2014.05.065","article-title":"Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants","volume":"64","author":"Cuker","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2017.06.034_bb0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy)","volume":"63","author":"Reilly","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.thromres.2017.06.034_bb0025","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1517\/14740338.2015.1049995","article-title":"Dose tailoring of dabigatran etexilate: obvious or excessive?","volume":"14","author":"Douxfils","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.thromres.2017.06.034_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/jth.12149","article-title":"Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis","author":"Baglin","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0035","doi-asserted-by":"crossref","first-page":"345138","DOI":"10.1155\/2015\/345138","article-title":"Non-VKA oral anticoagulants: accurate measurement of plasma drug concentrations","volume":"2015","author":"Douxfils","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.thromres.2017.06.034_bb0040","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1160\/TH13-03-0202","article-title":"Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS\/MS for the therapeutic monitoring of patients treated with dabigatran etexilate","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0045","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1160\/TH13-04-0274","article-title":"Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS\/MS for the therapeutic monitoring of patients treated with rivaroxaban","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/jth.13486","article-title":"Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter\/multiplatform study","author":"Testa","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0055","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0036-1597296","article-title":"Laboratory assessment of direct oral anticoagulants","volume":"43","author":"Douxfils","year":"2017","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/CIRCULATIONAHA.116.022307","article-title":"Urgent need to measure effects of direct oral anticoagulants","volume":"134","author":"Weitz","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2017.06.034_bb0065","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1160\/TH12-11-0842","article-title":"Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study","volume":"109","author":"Exner","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0070","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.thromres.2015.02.020","article-title":"Does the Russell viper venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study","volume":"135","author":"Douxfils","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2017.06.034_bb0075","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.5858\/arpa.2013-0750-OA","article-title":"Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban","volume":"138","author":"Gosselin","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.thromres.2017.06.034_bb0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-9560-12-7","article-title":"Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs","volume":"12","author":"Altman","year":"2014","journal-title":"Thromb. J."},{"key":"10.1016\/j.thromres.2017.06.034_bb0085","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/ijlh.12528","article-title":"Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays","volume":"38","author":"Gosselin","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.thromres.2017.06.034_bb0090","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1160\/TH14-09-0808","article-title":"Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays","volume":"113","author":"Douxfils","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0095","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jpba.2013.02.007","article-title":"Rapid determination of apixaban concentration in human plasma by liquid chromatography\/tandem mass spectrometry: application to pharmacokinetic study","volume":"78-79","author":"Delavenne","year":"2013","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.thromres.2017.06.034_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.thromres.2017.06.034_bb0105","author":"European Medicines Agency"},{"key":"10.1016\/j.thromres.2017.06.034_bb0110","author":"European Medicines Agency"},{"key":"10.1016\/j.thromres.2017.06.034_bb0115","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pathol.2015.11.025","article-title":"The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples","volume":"48","author":"Bonar","year":"2016","journal-title":"Pathology"},{"key":"10.1016\/j.thromres.2017.06.034_bb0120","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1160\/TH12-12-0898","article-title":"Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0125","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0130","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","article-title":"Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature","volume":"130","author":"Douxfils","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2017.06.034_bb0135","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/jth.13020","article-title":"Mixing studies in lupus anticoagulant testing are required at least in some type of samples","volume":"13","author":"Devreese","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0140","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/ijlh.12138","article-title":"Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin","volume":"36","author":"Martinuzzo","year":"2014","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.thromres.2017.06.034_bb0145","article-title":"Dilute Russell's viper venom time reagents in lupus anticoagulant testing: a well-considered choice","author":"Depreter","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.thromres.2017.06.034_bb0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/MBC.0000000000000382","article-title":"Measuring dabigatran with the dilute Russell viper venom confirm assay in an anticoagulation clinic population","volume":"27","author":"McGlasson","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2017.06.034_bb0155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1160\/TH14-02-0161","article-title":"Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey","volume":"113","author":"Van Blerk","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0160","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1515\/cclm-2014-0767","article-title":"Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?","volume":"53","author":"Lippi","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.thromres.2017.06.034_bb0165","first-page":"115","article-title":"Edoxaban: impact on routine and specific coagulation assays. A practical laboratory guide","author":"Douxfils","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0170","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2017.06.034_bb0175","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1161\/STROKEAHA.115.010148","article-title":"Point-of-care testing of coagulation in patients treated with non-vitamin K antagonist oral anticoagulants","volume":"46","author":"Ebner","year":"2015","journal-title":"Stroke"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384817303985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384817303985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T10:51:12Z","timestamp":1620816672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384817303985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":35,"alternative-id":["S0049384817303985"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2017.06.034","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2017.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}